A new diagnostic method has been developed

Parkinson's disease is a common neurodegenerative disease. There are more than two million patients in China, and the incidence in the elderly over 65 years is about 1.7%. Parkinson's disease mainly affects human motor function, and its common symptoms include slow movement, limb rigidity, tremor at rest posture and gait disorders. Many patients also have sleep disorders and anxiety symptoms. Parkinson's disease. For the problem of early diagnosis, British scientists recently released a method of early diagnosis of Parkinson's disease by detecting cerebrospinal fluid.

This method developed by researchers from the University of Edinburgh makes use of a lot of recombinant proteins such as recombinant mouse proteins and is aimed at one of the culprits for Parkinson's disease - a protein called α-synuclein. α-synuclein protein can be combined with each other in the nerve cells to form a structure called Lewy body. Lewy body would damage the normal function of nerve cells, leading to Parkinson's disease and Lewy body dementia which is closely related to Parkinson's disease. The difficulty of detecting α-synuclein lies in that normal nerve cells also produce this kind of protein. Only when its viscosity shows changes, they would combine with each other to form Lewy bodies.

Researchers at Edinburgh University used a technology called real-time vibration-induced conversion (RT-QuIC) to specially detect those α-synuclein proteins which are more easily to bind to each other with higher viscosity. In early experiments, this detection method successfully diagnosed 19 cases from 20 cerebrospinal fluid samples of patients with Parkinson, and the accuracy rate of 95%. While in 15 control samples, none showed false positive, and the specificity was 100%. What's more important, this test successfully separated the Lewy body dementia and Alzheimer's disease in the control group samples, showing its sensitivity and specificity.

The corresponding author of the study, Dr. Alison Green at University of Edinburgh said, "We have successfully applied this technology which had been proved in the diagnosis of BSE to Parkinson's disease. We hope to further improve it to help it better apply to the early diagnosis of Parkinson's disease. The earlier the diagnosis is, the earlier the treatment can help patients sooner to participate in the latest clinical trials."

Next, the researchers plan to start a large-scale clinical diagnostic test for Parkinson's disease in order to achieve the same high accuracy and specificity. We hope that this method of early diagnosis can be put into practice as soon as possible to help patients to start treatment as early as possible in order to obtain better results. Flarebio provides you with high-quality recombinant proteins like recombinant Cdh9.